Treatment Responses | Non-RASI, n = 17 | RASI, n = 40 | p |
---|---|---|---|
eGFR, ml/min/1.73m2 | 89 (68–98) | 90 (62–102) | 0.800 |
Improvement ratio, % | −2 (−20 to 20) | 26 (−5 to 86) | 0.028 |
MAP, mmHg | 89 ± 8; 90 (67–100) | 94 ± 11; 93 (77–123) | 0.130 |
Improvement ratio, % | 8 ± 16; 0 (−7 to 17) | 12 ± 18; 14 (0–25) | 0.508 |
Proteinuria level, g/d | 0.3 (0.1–0.9) | 0.4 (0–0.9) | 0.403 |
Improvement ratio, % | 90 (55–95) | 90 (81–96) | 0.457 |
Data in bold face are statistically significant. SLE: systemic lupus erythematosus; aPLN: antiphospholipid-associated nephropathy; IQR: interquartile range; RASI: renin-angiotensin system inhibitor; eGFR: estimated glomerular filtration rate; MAP: mean arterial blood pressure.